

Saturday, April 21 - Tuesday, April 24

Madrid, Spain

## **ECCMID 2018**

Fourteen poster presentations, including four oral sessions, will feature Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, Venatorx's President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company's R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.

VNRX-5133 is a new-generation beta-lactamase inhibitor (BLI) with unique broad-spectrum activity, covering both serine- and metallo-beta-lactamases. Venatorx is developing VNRX-5133 in a fixed combination with the 4<sup>th</sup> generation cephalosporin, cefepime. Venatorx believes that cefepime/VNRX-5133 has the potential to become a valuable treatment option for infections caused by multi-drug resistant (MDR) gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE) and *Pseudomonas aeruginosa*, suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens, and bioterror pathogens such as *Burkholderia spp.* and *Salmonella spp.*

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, [National Institutes of Health](#), Department of Health and Human Services, under Contract No. HHSN272201300019C, and [Wellcome Trust](#) under Award No. 360G-Wellcome-101999/Z/13/Z.

The oral sessions and paper poster session, featuring Venatorx's lead candidate, will be held as follows:

### **ePoster Mini Oral Sessions**

[Session #OE112 | Beta-lactamase inhibitors: from bench to bedside](#)

April 22, 2018

Location: ePoster Arena 3

**Oral Session #O0600. Time 16:00 – 16:05 CET** — *Efficacy of cefepime / VNRX-5133, a novel beta-lactamase inhibitor combination, against cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-*

*infection model.* W. Weiss, M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, D. Pevear, C. Burns and L. Xerri.

**Oral Session #O0603. Time 16:18 – 16:23 CET** — *Structural basis for serine- and metallo-beta-lactamase inhibition by VNRX-5133, a new beta-lactamase inhibitor (BLI) in clinical development.* J.D. Docquier, F. De Luca, M. Benvenuti, C. Pozzi, D. Daigle, D. Pevear, C. Burns and S. Mangani.

**Oral Session #O0606. Time 16:36 – 16:41 CET** — *Kinetic mechanism and parameters of inhibition of serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum beta-lactamase inhibitor VNRX-5133.* D. Daigle, C. Burns and D. Pevear.

### **2-Hour Oral Sessions with Mini-Review**

[Session #OS108 | Drug combinations: pre-clinical evidence](#)

April 22, 2018

Location: Hall L

**Oral Presentation #O0575. Time 16:34 – 16:44 CET** — *Pharmacodynamics of the novel broad-spectrum beta-lactamase inhibitor VNRX-5133 in combination with cefepime in neutropenic female CD-1 mice with experimental pneumonia.* P-C. Georgiou, M. Siopi, M. Tsala, C. Lagarde, W. Kloezen, R. Donnelly, J. Mouton and J. Meletiadis.

### **Paper Poster Session #76 (PS076)**

[VNRX-5133 plus cefepime: \*in vitro\* and \*in vivo\* data](#)

April 23, 2018

12:30pm – 13:30pm CET

Location: Paper Poster Arena

**Paper poster #P1536** — *Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known beta-lactamases.* S. Mushtaq, A. Vickers, N. Woodford and D. Livermore.

**Paper poster #P1537** — *Pharmacokinetics-pharmacodynamics (PK-PD) of VNRX-5133, a broad-spectrum novel beta-lactamase inhibitor (BS-BLI), in combination with cefepime in a one-compartment *in vitro* infection model.* B.D. VanScoy, J. McCauley, E.A. Lakota, H. Conde, S.M. Bhavnani, T. Henkel, L. Xerri, D. Pevear and P.G. Ambrose.

**Paper poster #P1538** — *Efficacy of cefepime / VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, in a murine bacteremia infection*

*model with carbapenem-resistant Enterobacteriaceae (CREs).* W. Weiss, M. Pulse, P. Nguyen, D. Valtierra, D. Pevear, C. Burns and L. Xerri.

**Paper poster #P1539** — *In vitro activity of cefepime alone and in combination with the broad-spectrum beta-lactamase inhibitor VNRX-5133 against ESBL and carbapenamases harbouring Enterobacteriaceae and Pseudomonas spp.* R. Donnelly, W. Kloezen, M. Goldman, A.C. Van Mil, C. Lagarde, J. Meletiadis and J. Mouton.

**Paper poster #P1540** — *VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, enhances the activity of cefepime against Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mouse thigh infection model.* P-C. Georgiou, M. Siopi, M. Tsala, C. Lagarde, W. Kloezen, R. Donnelly, J. Meletiadis and J. Mouton.

**Paper poster #P1541** — *Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant Enterobacteriaceae producing serine- and metallo-beta-lactamases.* J. Tyrrell, M. Wali, D. Daigle, A.F. Aboklaish, N. Kurepina, B. Kreiswirth, T.R. Walsh, D. Pevear and L. Xerri.

**Paper poster #P1542** — *In vitro activity of cefepime in combination with VNRX-5133 against meropenem and/or cefepime resistant clinical isolates of Pseudomonas aeruginosa.* M. Estabrook, M. Hackel and D. Sahn.

**Paper poster #P1543** — *Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates.* M. Hackel and D. Sahn.

**Paper poster #P1544** — *In vitro activity of cefepime in combination with VNRX-5133 when tested against cephalosporin and carbapenem resistant beta-lactamase producing gram-negative isolates.* K. Kazmierczak, M. Hackel and D. Sahn.

**Paper poster #P1545** — *The ability of broad-spectrum beta-lactamase inhibitor VNRX-5133 to restore bactericidal activity of cefepime in Enterobacteriaceae- and P. aeruginosa-expressing Ambler class A, B, C and D enzymes is demonstrated using time-kill kinetics.* J. Hamrick, C. Chatwin, K. John, D. Pevear, C. Burns and L. Xerri.